Fludarabine phosphate in chronic lymphoproliferative diseases. The French Group on CLL.

Abstract	The review of Phase II trials in patients treated by Fludarabine phosphate (Fludara I.V) has been demonstrated to have unequivocal benefit for some patients with Chronic Lymphocytic Leukemia (CLL) non Hodgkin lymphoma and macroglobulinemia. Comparison of Fludara I.V with other treatment regimens is now studied in randomised protocols for B and C stages of CLL.
Authors	J L Binet
Journal	Nouvelle revue francaise d'hematologie (Nouv Rev Fr Hematol (1978)) Vol. 35 Issue 1 Pg. 5-7 (Feb 1993) Germany
PMID	7685518 (Publication Type: Journal Article, Review)
Chemical References	Antimetabolites, Antineoplastic Vidarabine Phosphate fludarabine phosphate
Topics	Antimetabolites, Antineoplastic (therapeutic use) Clinical Trials, Phase II as Topic Humans Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy) Lymphoma, Non-Hodgkin (drug therapy) Lymphoproliferative Disorders (drug therapy) Vidarabine Phosphate (analogs & derivatives, therapeutic use) Waldenstrom Macroglobulinemia (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!